You are here

Article Text

Article menu
Download PDFPDF
Editorial
Airway microbiome studies challenge simplistic models of inhaled tobramycin benefit

http://dx.doi.org/10.1136/thoraxjnl-2020-216005

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors GBR was the sole contributor.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Provenance and peer review Commissioned; externally peer reviewed.

    Linked Articles

    • Cystic fibrosis
      Sputum microbiota in adults with CF associates with response to inhaled tobramycin
      Alya Heirali Christina Thornton Nicole Acosta Ranjani Somayaji Isabelle Laforest Lapointe Douglas Storey Harvey Rabin Barbara Waddell Laura Rossi Marie Claire Arrieta Michael Surette Michael D Parkins
      Thorax 2020; 75 1058-1064 Published Online First: 02 Nov 2020. doi: 10.1136/thoraxjnl-2019-214191
    • Respiratory infection
      Maintenance tobramycin primarily affects untargeted bacteria in the CF sputum microbiome
      Maria T Nelson Daniel J Wolter Alexander Eng Eli J Weiss Anh T Vo Mitchell J Brittnacher Hillary S Hayden Sumedha Ravishankar Gilbert Bautista Anina Ratjen Marcella Blackledge Sharon McNamara Laura Nay Cheryl Majors Samuel I Miller Elhanan Borenstein Richard H Simon John J LiPuma Luke R Hoffman
      Thorax 2020; 75 780-790 Published Online First: 06 Jul 2020. doi: 10.1136/thoraxjnl-2019-214187